These biotech companies are supposed to curb infections

Frankfurt With the series of monkeypox infections, a new infectious disease has suddenly come to the fore in Europe and the USA. Compared to Sars-CoV2, however, the starting position of the physicians appears to be significantly more favorable. Because, in principle, both vaccines and drugs are available to combat the disease, albeit by far not in the quantities that would be necessary for widespread coverage.

These are all vaccines and active ingredients that were originally developed against the variola virus – the causative agent of smallpox. Variola and monkeypox virus are relatively closely related, so vaccines and drugs developed with the risk of using smallpox as a biological weapon are effective against the new disease. The biotech companies active in the field, including the Danish-German biotech company Bavarian Nordic, have posted some significant double-digit price gains in the past few days.